// App-Quantinova.ai

P682 : NEMTABRUTINIB (MK-1026), A NON-COVALENT INHIBITOR OF WILD-TYPE AND C481S MUTATED BRUTON TYROSINE KINASE FOR B-CELL MALIGNANCIES: EFFICACY AND SAFETY OF THE PHASE 2 DOSE-EXPANSION BELLWAVE-001 STUDY

Researchers

Presenter

  • Jennifer Woyach

Principal Investigators

  • Ian W. Flinn

  • Farrukh T. Awan

  • Herbert Eradat

  • Danielle Brander

  • Sameer A. Parikh

  • Tycel Phillips

  • Wayne Wang

  • Nishitha M. Reddy

  • Mohammed Z.H. Farooqui

  • John C. Byrd

  • Deborah M. Stephens

Medical Centers

  • Duke Cancer Institute, Duke University Medical Center, Durham, NC

  • Division of Hematology,The Ohio State University, Columbus,Columbus,Stati Uniti

  • Duke Cancer Institute, Duke University Medical Center, Durham, NC

  • Department of Internal Medicine,University of Cincinnati College of Medicine,Cincinnati,United

  • Co., Inc.,Kenilworth,United States

  • Division of Hematopathology, Mayo Clinic, Rochester, MN

  • Division of Hematology,The Ohio State University, Columbus,Columbus,Stati Uniti

  • Department of Hematology-Oncology,David Geffen School of Medicine at UCLA,Los Angeles,Stati Uniti

  • Colorado Blood Cancer Institute,Denver,Vereinigte Staaten

  • Division of Rheumatology, FMUSP

  • Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX

  • Colorado Blood Cancer Institute,Denver,Vereinigte Staaten

  • Division of Hematology and Oncology,University of Michigan Rogel Cancer Center,Ann Arbor,Stati Uniti

  • Colorado Blood Cancer Institute,Denver,Estados Unidos

  • Division of Hematology,The Ohio State University, Columbus,Columbus,Stati Uniti

  • Colorado Blood Cancer In

  • Colorado Blood Cancer Institute,Denver,Estados Unidos

  • Division of Hematology, Mayo Clinic,Rochester, MN,États-unis

  • Merck &amp

  • Veristat, LLC,Southborough, MA,United States

  • Division of Hematology and Oncology,University of Michigan Rogel Cancer Center,Ann Arbor,Stati Uniti

  • Co., Inc.,Kenilworth,Vereinigte Staaten

  • Co., Inc, Kenilworth, NJ

  • Hematology and Hematologic Malignancies, University of Utah Huntsman Cancer Institute, Salt Lake City, UT

  • Division of Hematology,The Ohio State University, Columbus,Columbus,Stati Uniti

  • Department of Hematology-Oncology,David Geffen School of Medicine at UCLA,Los Angeles,United States

  • Division of Epidemiology, Mayo Clinic, Rochester, United States

  • Co., Inc.,Kenilworth,Vereinigte Staaten

  • 2Colorado Blood Cancer Institute Denver CO United States

  • Co., Inc.,Kenilworth, NJ,États-unis

  • Sarah Cannon Center Research

  • Veristat, LLC,Southborough,Stati Uniti

  • Veristat, LLC,Southborough,USA

  • Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX

  • Veristat, LLC,Southborough, MA,United States

  • Division of Hematology,Mayo Clinic,Rochester,Verenigde Staten

  • Division of Hematology/Oncology, University of Michigan School of Medicine, Ann Arbor, MI

  • Colorado Blood Cancer Institute,Denver,Estados Unidos

  • Division of Hematology,The Ohio State University, Columbus,Columbus,Stati Uniti

  • Division of Hematology,Mayo Clinic,Rochester,Verenigde Staten

  • Division of Hematology, Mayo Clinic,Rochester, MN,États-unis

  • Duke Cancer Institute, Duke University Medical Center, Durham, NC

  • Duke Cancer Institute, Duke University Medical Center, United States

  • Co., Inc.,Kenilworth,Stati Uniti

  • Department of Internal Medicine,University of Cincinnati College of Medicine,Cincinnati,United

  • Department of Internal Medicine,University of Cincinnati College of Medicine,Cincinnati,United

  • Veristat, LLC,Southborough, MA,United States

  • Division of Hematology and Hematologic Malignancies,Huntsman Cancer Institute,Salt Lake City,Vereinigte Staaten

  • Co., Inc.,Kenilworth,Estados Unidos

  • Veristat, LLC,Southborough,Estados Unidos

  • Hematology and Hematologic Malignancies, University of Utah Huntsman Cancer Institute, Salt Lake City, UT

  • Duke Cancer Institute, Duke University Medical Center, Durham, NC

  • Division of Hematology, Mayo Clinic,Rochester, MN,États-unis

  • Department of Hematology-Oncology,David Geffen School of Medicine at UCLA,Los Angeles,Stati Uniti

  • Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX

  • Division of Hematology and Oncology,University of Michigan Rogel Cancer Center,Ann Arbor,Stati Uniti

  • Veristat, LLC,Southborough, MA,États-unis

  • Department of Hematology-Oncology,David Geffen School of Medicine at UCLA,Los Angeles,Stati Uniti

  • Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX

  • Duke Cancer Institute, NC

  • Department of Internal Medicine,University of Cincinnati College of Medicine,Cincinnati,United

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Oncology (ONC)

Disease

  • Mucosa-associated lymphoid tissue lymphoma

  • Mantle cell lymphoma

  • B cell lymphomas

  • Follicular lymphoma

  • B-Cell Non-Hodgkin Lymphoma

  • Lymphomas

Biomarkers

  • B-cell lymphoma 6

  • cMYC

Drug/Treatment

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Open Label

  • Single Arm

  • Cohort

Phase

  • N/A

Study Id's

  • NCT03162536

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved